WO2013120058A2 - Nouveaux peptides sp-b et sp-c, tensioactifs pulmonaires synthétiques, et leurs utilisations - Google Patents
Nouveaux peptides sp-b et sp-c, tensioactifs pulmonaires synthétiques, et leurs utilisations Download PDFInfo
- Publication number
- WO2013120058A2 WO2013120058A2 PCT/US2013/025532 US2013025532W WO2013120058A2 WO 2013120058 A2 WO2013120058 A2 WO 2013120058A2 US 2013025532 W US2013025532 W US 2013025532W WO 2013120058 A2 WO2013120058 A2 WO 2013120058A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- surfactant
- ion
- peptide
- datk
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to novel peptides and their use in surfactant compositions, as well as various uses of the surfactant compositions.
- pulmonary surfactant a complex mixture containing glycerophospholipids and specific surfactant proteins (SP) that is synthesized by type II epithelial cells in the alveolar lining
- SP surfactant proteins
- the mammalian lungs have a huge internal surface area of the order 1 m 2 /kg body weight at total lung capacity, and much of this surface is lined by a thin liquid film or "alveolar hypophase".
- Surface tension forces at the extensive air-hypophase interface are a major contributor to the work of breathing.
- Pulmonary surfactant plays crucial roles in respiratory physiology by moderating these surface tension forces.
- Endogenous surfactant secreted by alveolar type II epithelial cells adsorbs at the air-hypophase interface and lowers and varies surface tension as a function of alveolar size during breathing. This regulation of surface tension reduces the work of breathing while stabilizing different sized alveoli against collapse and overdistension. It also leads to a smaller hydrostatic pressure driving force for edema fluid to move into the lung interstitium from the pulmonary capillaries.
- NRDS neonatal respiratory distress syndrome
- HMD Hyaline Membrane Disease
- ALI and ARDS are lethal manifestations of inflammatory lung injury that can result from multiple direct and indirect causes ranging from respiratory infection, gastric aspiration, meconium aspiration, blunt chest trauma with lung contusion, hyperoxia, near drowning, hypovolemic shock, bacterial sepsis, and many others (for review see Notter et al, editors, Lung Injury: Mechanisms, Pathophysiology and Therapy, Taylor Francis Group, Inc, Boca Raton (2005)).
- ALI/ ARDS can affect patients of all ages from infants to adults, although different age groups vary somewhat in the etiology and specifics of disease.
- ARDS The Consensus Committee defined ALI identically to ARDS except for a Pa0 2 /Fi0 2 ratio ⁇ 300 mmHg (Bernard et al., "The American-European Consensus Conference on ARDS: Definitions, Mechanisms, Relevant Outcomes, and Clinical Trial Coordination," Am J Respir Crit Care Med 149:818-824 (1994)).
- ARDS affects 50,000 to 150,000 patients in the United States each year, and the incidence of ALI is estimated at 22-86 cases per 100,000 people per year.
- exogenous surfactants used in treating ALI/ARDS and/or severe NRDS must have very high surface activity and resistance to biophysical inhibition and/or chemical degradation.
- endogenous surfactant is deficient or dysfunctional, it can in principle be treated by the delivery of active exogenous surface-active material to the alveoli by airway instillation or by other techniques such as aerosolization or nebulization.
- Exogenous surfactant therapy is intended to preserve lung function over the short term while the patient's lungs develop or recover the ability to produce and maintain adequate levels of endogenous surfactant.
- exogenous surfactant therapy with first- generation animal-derived clinical surfactant drugs to prevent or treat NRDS in premature infants is well documented (for review see: Notter, Lung Surfactants: Basic Science and Clinical Applications, Marcel Dekker, Inc, New York (2000); Soil,
- synthetic lung surfactants manufactured under controlled conditions have significant potential advantages in purity, compositional reproducibility, activity reproducibility, quality-control, and manufacturing economy compared to animal-derived preparations.
- constituents in synthetic surfactants can incorporate special and useful molecular properties, such as resistance to degradation by phospholipases during inflammatory lung injury ((Notter, Lung Surfactants: Basic Science and Clinical Applications, Marcel Dekker, Inc, New York (2000); Wang et al, "Surface Activity of a Synthetic Lung Surfactant Containing a Phospholipase-resistant Phosphonolipid Analog of Dipalmitoyl Phosphatidylcholine,” Am J Physiol 285:L550- L559 (2003); Wang et al., “Activity and Inhibition Resistance of a Phospholipase- Resistant Synthetic Exogenous Surfactant in Excised Rat Lungs,” Am J Respir Cell Mol Biol 37:387-394 (2007)).
- Synthetic surfactants are also free from concerns about prion- caused diseases (e.g., bovine spongiform encephalitis) that are relevant for animal- derived surfactants, and synthetic surfactants are not subject to cultural or religious considerations that potentially affect bovine- or porcine-derived preparations.
- prion- caused diseases e.g., bovine spongiform encephalitis
- the present invention is directed to overcoming these and other deficiencies in the art.
- a first aspect of the present invention relates to a novel surface active peptide.
- the surface active peptide is derived from SP-B and comprises the consensus amino acid sequence of:
- XWLXRALIKRIQAMI-Z-RMLPQLVXRLVLRXS (SEQ ID NO: 1) where Z is a loop or turn sequence containing at least four amino acids, and each X independently represents an uncharged amino acid residue, except that Z is not PKGG when each X is cysteine.
- the surface active peptide is derived from SP-B and comprises the consensus amino acid sequence of:
- XWLXRALIKRIQAXI-Z-RXLPQLVXRLVLRXS (SEQ ID NO: 414) where Z is a loop or turn sequence containing at least four amino acids, each X at positions 1, 4, 24, and 30 independently represents an uncharged amino acid residue and each X at positions 14 and 18 independently represent leucine, isoleucine, or norleucine, except that Z is not PKGG when each X at positions 1, 4, 24, and 30 is cysteine.
- the surface active peptide is derived from SP-C and comprises the consensus amino acid sequence of:
- XXIPXXPXXLK LLXXXXX (SEQ ID NO: 30) where X at the first position is Leu or Phe, X at the second position is Gly or Arg, X at the fifth position is Phe, Cys, or Tyr, X at the sixth position is Phe or Tyr, X at the eighth position is Ser or Val, X at the ninth position is Ser or His, X at the fifteenth and sixteenth positions is independently He or Val, and X at the seventeenth to nineteenth positions is independently Val or Leu.
- the surface active peptide is derived from SP-C and comprises the consensus amino acid sequence of:
- GIPXXPXXLKRLLIXVVVXXLXVXVIVGALLMG (SEQ ID NO: 36) where X at the fourth and fifth positions are independently Ser or Phe; X at the seventh position is Val or Ser; X at the eighth position is His or Ser; X at positions 15 and 19 and 20 and 24 represent one or two pairs of residues that can form an ion lock, except that when only one pair forms an ion lock, then the other residues are a hydrophobic amino acid selected from Leu, He, and Val; and X at position 22 is He or Val; wherein the amino acids residues that can form the ion lock are positively-charged or negatively- charged amino acids.
- the surface active peptide is derived from SP- C and comprises the consensus amino acid sequence of:
- IPXXPXXLKRLKLLXLLLXXILLXILGALLMGL (SEQ ID NO: 325) where X at positions 3 and 4 are independently Ser or Phe; X at position 6 is Val or Ser; X at position 7 is His or Ser; X at positions 15 and 19 and 20 and 24 represent one or two pairs of residues that can form an ion lock, except that when only one pair forms an ion lock, then the other residues are a hydrophobic amino acid selected from Leu, He, and Val.
- a second aspect of the present invention relates to a surfactant composition that includes a surface active peptide of the first aspect of the invention.
- the surfactant composition also includes one or more synthetic phospholipids.
- the synthetic phospholipids can be one or more glycerophospholipids found in endogenous surfactants (including exogenous surfactant formulations), one or more phospholipase- resistant phospho-glycerol derivatives, one or more phospholipase-resistant phospho- choline derivatives, or a combination thereof.
- a third aspect of the present invention relates to a method of treating endogenous surfactant dysfunctional lung tissue.
- This includes providing a surfactant composition according to the second aspect of the present invention, and administering the surfactant composition to a patient having lung tissue characterized by endogenous surfactant deficiency and/or dysfunction.
- the administering is carried out under conditions effective to coat alveolar surfaces of the affected lung tissue with the surfactant composition, thereby treating the surfactant deficient and/or dysfunctional lung tissue.
- a fourth aspect of the present invention relates to a method of delivering a therapeutic agent.
- the method includes introducing a therapeutic agent into a surfactant composition according to the second aspect of the present invention under conditions effective to encapsulate the therapeutic agent in liposomal vesicles.
- the method also involves administering the composition to a subject under conditions effective to deliver the therapeutic agent to a target tissue, including airway instillation or aerosol delivery.
- the present invention achieves a synthetic lung surfactant composition that overcomes the above-identified deficiencies through the use of synthetic surface- active peptides that are remarkably stable and easy to synthesize.
- several synthetic compositions of the present invention can achieve high surface activity approaching, equaling or exceeding animal-derived surfactants, while incorporating commercially relevant advantages in synthesis, purity, compositional reproducibility, manufacturing quality control, and/or stability compared to animal-derived materials.
- the synthetic surfactants of this invention are also free from the risk of transmitting animal pathogens such as prions (e.g., bovine spongiform encephalitis).
- Lipids Synthetic lipids alone. Synthetic lipids are DPPC:POPC:POPG (5:3:2, weight ratio).
- Figure 2 is a pair of graphs illustrating arterial oxygenation and dynamic compliance in surfactant SP-C mimic-treated, ventilated rabbits with ARDS induced by in vivo lavage. Arterial partial pressure of oxygen and dynamic compliance are shown for groups of rabbits treated with synthetic preparations containing synthetic lipids with 3.0% by weight SP-C33 (SEQ ID NO: 397), SP-C ss ion-lock (SEQ ID NO: 45), SP-Cff (SEQ ID NO: 396).
- Lipids Synthetic lipids alone. Synthetic lipids are
- DPPC:POPC:POPG 5:3:2, weight ratio.
- the present invention relates to surface-active synthetic peptides and lung surfactant compositions that contain one or more of these peptides.
- surface-active synthetic peptide is meant to include a synthetic peptide that increases the ability of the surfactant composition to lower surface tension during adsorption and/or during dynamic compression in a spread or adsorbed interfacial (surface) film.
- Preferred "surface-active synthetic peptides” are amphipathic or hydrophobic.
- the surface-active synthetic peptides of the present invention have been designed to have optimal surface-active interactions with phospholipids, including phospholipase-resistant phospholipids, when present in surfactant compositions of the present invention. These peptides can also be used to form highly-active synthetic surfactants in combination with non phospholipase-resistant phospholipids, including phospholipids present in endogenous surfactant or commercially available exogenous surfactant preparations.
- the surface-active synthetic peptides of this invention can be related in primary sequence to regions of surfactant proteins (SP)-B or SP-C, and may also incorporate features such as homo- or hetero-dimerization.
- SP surfactant proteins
- amphipathic peptides for this invention are those related to the regional or full-length sequence of human or animal SP-B, including dimer forms, which may be used in synthetic lung surfactants with lipids as single peptides or in combination with preferred synthetic peptides related to the regional or full sequence of SP-C.
- Preferred peptides can be combined in synthetic exogenous surfactants with 'regular' (e.g., ester-linked) synthetic phospholipids including those found in native lung surfactant or with phospholipase-resistant synthetic phospholipids.
- fragments of the mature SP-B and/or SP-C are employed in the surfactant compositions of the present invention, it is preferable to utilize fragments thereof that contain at least a portion of a lipid associating region.
- Lipid associating regions are those portions of the mature protein that are capable of molecular interaction with lipids (either native glycerophospholipids or synthetic phospholipase-resistant lipids) to promote surface activity of the resulting composition in which they are introduced.
- Such fragments include, without limitation, fragments of SP-B that contain an amphipathic or hydrophobic region capable of associating with lipids, fragments of SP-C that contain an amphipathic or hydrophobic region capable of associating with lipids, as well as any number of synthetic peptides or combinations thereof.
- the synthetic peptides can be modified not only with respect to their primary amino acid sequence (i.e., relative to SP-B or SP-C), but also by the presence of structural features that affect tertiary structure of the peptide. These structural features may include, among others, the presence of modified beta-turn peptide structures, ion- lock residues, the presence of di-sulfide linkages between two peptide sequences to form a single dimeric molecule, and the presence of fatty acid chains tethered via disulfide bond to a Cys residue in the peptide.
- a first synthetic peptide family of the present invention has molecular features analogous to SP-B and is designed to include peptides comprising the consensus amino acid sequence of:
- XWLXRALIKPJQAMI-Z-RMLPQLVXRLVLRXS (SEQ ID NO: 1) where Z is a loop or turn sequence containing at least four amino acids, and each X independently represents an uncharged amino acid residue.
- the loop or turn sequence (-Z-) can be any suitable sequence, but is preferably selected from the group of four to ten amino acid residues that include the peptides PKGG, DATK, DHGS, HSGD, or EAGD.
- the loop or turn sequence (-Z-) consists of PKGG, DATK, DHGS, HSGD, or EAGD.
- the hydrophobic amino acid residues (X) can be valine, isoleucine, leucine, methionine, phenylalanine, tryptophan, histidine, tyrosine, glycine, alanine, cysteine, proline, asparagine, glutamine, and serine. Of these, alanine, serine, threonine, and cysteine are preferred, with cysteine, alanine, and serine being most preferred.
- SEQ ID NO: 1 the scope of SEQ ID NO: 1 is intended to include peptide sequences where Z consists of PKGG and each X is cysteine.
- Peptide sequences of this type have been previously identified as Mini-B (Waring et al, "The Role of Charged Amphipathic Helices in the Structure and Function of Surfactant Protein B," Journal Peptide Research 66:364-374 (2005); U.S. Patent No. 7,538,090 to Waring et al., each of which is hereby incorporated by reference in its entirety) and Super Mini-B (PCT Application Publ. No.
- Exemplary peptides that correspond to the peptide of SEQ ID NO: 1 include, without limitation, those listed in Table 1 below, as well as combinations thereof.
- MB means that the sequence is related to the peptide "Mini-B” (Waring et al., “The Role of Charged Amphipathic Helices in the Structure and Function of Surfactant Protein B,” Journal Peptide Research 66:364-374 (2005); U.S. Patent No. 7,538,090 to Waring et al.) and SMB means that the sequence is related to the peptide "Super-Mini-B” (PCT Application Publ. No. WO 2008/01 1559; Walther et al., “Critical Structural and Functional Roles for the N-terminal Insertion Sequence in Surfactant Protein B Analogs," PLoS One 5:e8672.10.1371 (2010)). Each reference is incorporated herein in its entirety.
- Peptides within the consensus family of SEQ ID NO: 1 include peptide sequences that comprise one of SEQ ID NOS: 2-29, as well as peptide sequences that consist of one of SEQ ID NOS: 2-29.
- a second synthetic peptide family of the present invention has molecule features analogous to SP-B and is designed to include peptides comprising the consensus amino acid sequence of:
- XWLXRALIKRIQAXI-Z-RXLPQLVXRLVLRXS (SEQ ID NO: 414) where Z is a loop or turn sequence containing at least four amino acids, each X at positions 1, 4, 24, and 30 independently represents an uncharged amino acid residue and each X at positions 14 and 18 independently represents leucine, isoleucine, or norleucine, except that Z is not PKGG when each X at positions 1, 4, 24, and 30 is cysteine.
- the peptide sequences of SEQ ID NO: 414 therefore differ from the peptides of SEQ ID NO: 1 with respect to the methionine residues at positions 14 and 18 of SEQ ID NO: 1, which are replaced in SEQ ID NO: 414 by leucine, isoleucine, or norleucine to prevent the methionine from oxidizing and making the peptide sequence more polar.
- the loop or turn sequence (-Z-) can be any suitable sequence, but is preferably selected from the group of four to ten amino acid residues that include the peptides PKGG, DATK, DHGS, HSGD, or EAGD.
- the loop or turn sequence (-Z-) consists of PKGG, DATK, DHGS, HSGD, or EAGD.
- the hydrophobic amino acid residues (X) can be valine, isoleucine, leucine, methionine, phenylalanine, tryptophan, histidine, tyrosine, glycine, alanine, cysteine, proline, asparagine, glutamine, and serine. Of these, alanine, serine, threonine, and cysteine are preferred, with cysteine, alanine, and serine being most preferred.
- SEQ ID NO: 414 is intended to include peptide sequences where Z consists of PKGG and X at positions 1, 4, 24, and 30 is cysteine.
- Peptide sequences of this type have been previously identified in U.S. Publ. No. 2011/0003733 to Pivetti et al. and Seehase et al, "New Surfactant with SP-B and C Analogs Gives Survival Benefit after Inactivation in Preterm Lambs," PLoS One 7(10): e47631 (2012), each of which is hereby incorporated by reference in its entirety.
- Embodiments where these peptides are included within the scope of the present invention include surfactant formulations where these peptides are included in combination with a novel SP-C-like peptide.
- SEQ ID NO: 414 is intended specifically to exclude such peptide sequences where Z consists of PKGG and X at positions 1, 4, 24, and 30 is cysteine, as described in the preceding paragraph.
- Embodiments where these peptides are specifically excluded from the scope of the present invention relate to the peptides of SEQ ID NO: 414, per se, and surfactant formulations where the SEQ ID NO: 414 peptides are included in combination with a previously known SP-C-like peptide.
- Exemplary peptides that correspond to the peptide of SEQ ID NO: 414 include, without limitation, those listed in Table 2 below, as well as combinations thereof.
- X represents Norleucine (Me).
- Peptides within the consensus family of SEQ ID NO: 414 include peptide sequences that comprise one of SEQ ID NOS: 415-498, as well as peptide sequences that consist of one of SEQ ID NOS: 415-498.
- a third synthetic peptide family of the present invention has molecular features analogous to SP-C and is designed to include peptides comprising the consensus amino acid sequence of:
- XXIPXXPXXLK LLXXXXX (SEQ ID NO: 30) where X at the first position is optional, and can be Leu or Phe, X at the second position is optional, and can be Gly or Arg, X at the fifth position is Phe, Cys, or Tyr, X at the sixth position is Phe or Tyr, X at the eighth position is Ser or Val, X at the ninth position is Ser or His, X at fourteenth position is Leu or Lys, X at the fifteenth and sixteenth positions is independently He, Leu, or Val, and X at the seventeenth to nineteenth positions is independently Val or Leu.
- Exemplary peptides that correspond to the peptide of SEQ ID NO: 30 include, without limitation, those listed in Table 3 below, as well as combinations thereof.
- Peptides within the consensus family of SEQ ID NO: 30 include peptide sequences that comprise one of SEQ ID NOS: 31-35 and 390, as well as peptide sequences that consist of one of SEQ ID NOS: 31-35 and 390.
- a fourth synthetic peptide family of the present invention has molecular features analogous to SP-C, but is modified to include one or more pairs of oppositely charged amino acid residues designed to form an ion lock.
- the peptides of this family comprise the consensus amino acid sequence of:
- GIPXXPXXLK LLIXVVVXXLXVXVIVGALLMG (SEQ ID NO: 36) where X at the fourth and fifth positions are independently Ser or Phe; X at the seventh position is Val or Ser; X at the eighth position is His or Ser; X at positions 15 and 19 and 20 and 24 represent one or two pairs of residues that can form an ion lock, except that when only one pair forms an ion lock, then the other residues are a hydrophobic amino acid selected from Leu, He, and Val; and X at position 22 is He or Val.
- the amino acids capable of forming an ion lock are positively-charged or negatively-charged amino acids, preferably Lys, Arg, Glu, or Asp, whereby when the amino acid at position 15 is positively charged then the amino acid at position 19 is negatively charged, or vice versa, and when the amino acid at position 20 is positively charged then the amino acid at position 24 is negatively charged, or vice versa.
- one ion lock pair may be present at positions 15/19, in which case the amino acids at positions 20/24 are hydrophobic; one ion lock pair may be present at positions 20/24, in which case the amino acids at positions 15/19 are hydrophobic; or two ion lock pairs can be present at positions 15/19 and at positions 20/24.
- Exemplary peptides that correspond to the peptide of SEQ ID NO: 36 include, without limitation, those listed in Table 4 below, as well as combinations thereof.
- Peptides within the consensus family of SEQ ID NO: 36 include peptide sequences that comprise one of SEQ ID NOS: 37-324 and 398-413, as well as peptide sequences that consist of one of SEQ ID NOS: 37-324 and 398-413.
- a fifth synthetic peptide family of the present invention has molecular features analogous to SP-C and is designed to include peptides comprising the consensus amino acid sequence of:
- IPXXPXXLKRLKLLXLLLXXILLXILGALLMGL (SEQ ID NO: 325) where X at positions 3 and 4 are independently Ser or Phe; X at position 6 is Val or Ser; X at position 7 is His or Ser; X at positions 15 and 19 and 20 and 24 represent one or two pairs of residues that can form an ion lock, except that when only one pair forms an ion lock, then the other residues are a hydrophobic amino acid selected from Leu, He, and Val.
- the amino acids capable of forming an ion lock are positively-charged or negatively-charged amino acids, preferably Lys, Arg, Glu, or Asp, whereby when the amino acid at position 15 is positively charged then the amino acid at position 19 is negatively charged, or vice versa, and when the amino acid at position 20 is positively charged then the amino acid at position 24 is negatively charged, or vice versa.
- one ion lock pair may be present at positions 15/19, in which case the amino acids at positions 20/24 are hydrophobic; one ion lock pair may be present at positions 20/24, in which case the amino acids at positions 15/19 are hydrophobic; or two ion lock pairs can be present at positions 15/19 and at positions 20/24.
- Exemplary peptides that correspond to the peptide of SEQ ID NO: 325 include, without limitation, those listed in Table 5 below, as well as combinations thereof. Table 5: Members of SP-C-like Peptides with Ion-Lock
- Peptides within the consensus family of SEQ ID NO: 325 include peptide sequences that comprise one of SEQ ID NOS: 326-389, as well as peptide sequences that consist of one of SEQ ID NOS: 326-389. Specifically excluded from the scope of SEQ ID NO: 325 are peptides that consist of or consist essentially of
- the synthetic peptides of the present invention are designed with amino acid sequences that retard the transition of helical structures to non-specific or amyloidlike structures that have attenuated surface activity and/or increased surface or shear viscosity (Gordon et al., "Conformational Mapping of the N-Terminal Peptide of HIV- 1 gp41 in Lipid Detergent and Aqueous Environments Using 13 C-Enhanced Fourier Transform Infrared Spectroscopy," Protein Sci 13: 1012-1030 (2004), which is hereby incorporated by reference in its entirety).
- the synthetic peptides will increase shelf life as well as reduce surface or shear viscosity in synthetic lung surfactants to improve their ease of pulmonary delivery.
- the synthetic peptides of this invention are designed to allow the formulation of peptide- containing synthetic lung surfactants with salts containing calcium or other divalent or monovalent ions (as described above) so as to reduce surface or shear viscosity to improve pulmonary delivery as well as maximize shelf life.
- the synthetic peptides of the present invention can be synthesized by standard peptide synthesis operations. These include both FMOC (9- Fluorenylmethyloxy-carbonyl) and tBoc (tert-Butyl oxy carbonyl) synthesis protocols that can be carried out on automated solid phase peptide synthesis instruments including, without limitation, the Applied Biosystems 431 A, 433 A synthesizers and Peptide Technologies Symphony or large scale Sonata or CEM Liberty automated solid phase peptide synthesizers.
- FMOC Fluorenylmethyloxy-carbonyl
- tBoc tert-Butyl oxy carbonyl
- mimics of the surfactant peptides may also be prepared using either oligo-N-substituted glycines to make surface active surfactant peptoids (Seurynck et al, Chem.
- the synthetic peptides can be synthesized in the presence of one or more synthetic lipid analogs described below and in PCT Application Publ. No. WO 2008/011559, which is hereby incorporated by reference in its entirety.
- the surface-active peptides may be also prepared by using recombinant expression systems. Generally, this involves inserting the encoding nucleic acid molecule into an expression system to which the molecule is heterologous (i.e., not normally present). One or more desired nucleic acid molecules encoding a peptide of the invention may be inserted into the vector. When multiple nucleic acid molecules are inserted, the multiple nucleic acid molecules may encode the same or different peptides.
- the heterologous nucleic acid molecule is inserted into the expression system or vector in proper sense (5'—3') orientation relative to the promoter and any other 5' regulatory molecules, and correct reading frame.
- the nucleic acid molecules can be derived from the known SP-B and SP-
- nucleotides using the above-referenced Genbank Accessions.
- the nucleic acid molecules can be synthesized and then used for preparation of recombinant nucleic acid constructs.
- a consensus DNA sequence encoding the peptides of SEQ ID NO: 1 possesses a codon-optimized sequence for expression in E. coli as follows:
- SEQ ID NO: 391 where the 1 st , 4 th , 27 th , and 33 rd codons independently encode Ala, Ser, or Cys; and the 16 th - 19 th codons encode the peptide sequence consisting of the Z sequences noted above (e.g., PKGG, DATK, DHGS, HSGD, or EAGD).
- Specific codon-enhanced sequences for peptides of SEQ ID NOS: 2-29 can be identified using the online backtranslation tool available from Entelechon. The sequences can be modified at their ends to facilitate ligation into a nucleic acid construct or the presence of various regulatory sequences as described herein.
- a consensus DNA sequence encoding the peptides of SEQ ID NO: 414 possesses a codon-optimized sequence for expression in E. coli as follows:
- SEQ ID NO: 499 where the 1 st , 4 th , 27 th , and 33 rd codons independently encode Ala, Ser, or Cys; the 16 th - 19 th codons encode the peptide sequence consisting of the Z sequences noted above (e.g., PKGG, DATK, DHGS, HSGD, or EAGD); and the 14 th and 21 st codons encode Leu or Iso.
- Specific codon-enhanced sequences for peptides of SEQ ID NOS: 415-470 can be identified using the online backtranslation tool available from Entelechon. The sequences can be modified at their ends to facilitate ligation into a nucleic acid construct or the presence of various regulatory sequences as described herein.
- SEQ ID NO: 30 possesses a codon-optimized sequence for expression in E. coli as follows:
- SEQ ID NO: 36 possesses a codon-optimized sequence for expression in E. coli as follows:
- Specific codon-enhanced sequences for peptides of SEQ ID NOS : 37-324 and 398-413 can be identified using the online backtranslation tool available from Entelechon.
- the sequences can be modified at their ends to facilitate ligation into a nucleic acid construct or the presence of various regulatory sequences as described herein.
- a consensus DNA sequence encoding the peptides of SEQ ID NO: 325 possesses a codon-optimized sequence for expression in E. coli as follows:
- SEQ ID NO: 394 where the 3d and 4 codons independently encode either Ser or Phe; the 6 th codon encodes Val or Ser; the 7 th codon encodes His or Ser; at least one pair of the 15 th and 19 th codons and the 20 th and 24 th codons encode pairs of amino acid residues that can form an ion lock, as described above, except that when only one pair forms an ion lock, then the other pair encodes a hydrophobic amino acid independently selected from Leu, He, and Val.
- Specific codon-enhanced sequences for peptides of SEQ ID NOS: 37-324 and 398-413 can be identified using the online backtranslation tool available from Entelechon.
- sequences can be modified at their ends to facilitate ligation into a nucleic acid construct or the presence of various regulatory sequences as described herein.
- These DNA molecules can be ligated into a nucleic acid constructs or expression system using methods well known in the art.
- U.S. Patent No. 4,237,224 to Cohen and Boyer which is hereby incorporated by reference in its entirety, describes the production of expression systems in the form of recombinant plasmids using restriction enzyme cleavage and ligation with DNA ligase. These recombinant plasmids are then introduced by means of transformation and replicated in unicellular cultures including prokaryotic organisms and eukaryotic cells grown in tissue culture. Other vectors are also suitable.
- nucleic acid sequences are cloned into the vector using standard cloning procedures in the art, as described by Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Springs Laboratory, Cold Springs Harbor, New York (1989), or U.S. Patent No. 4,237,224 to Cohen and Boyer, which are hereby incorporated by reference in their entirety.
- the vector is then introduced to a suitable host.
- host- vector systems may be utilized to express the recombinant protein or polypeptide. Primarily, the vector system must be compatible with the host used.
- Host- vector systems include, without limitation, the following: bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA;
- microorganisms such as yeast containing yeast vectors; mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); and plant cells infected by bacteria.
- the expression elements of these vectors vary in their strength and specificities. Depending upon the host-vector system utilized, any one of a number of suitable transcription and translation elements can be used to carry out this and other aspects of the present invention.
- RNA transcription and messenger RNA Transcription of DNA is dependent upon the presence of a promoter, which is a DNA sequence that directs the binding of RNA polymerase, and thereby promotes mRNA synthesis.
- the DNA sequences of eukaryotic promoters differ from those of prokaryotic promoters.
- eukaryotic promoters and accompanying genetic signals may not be recognized in, or may not function in, a prokaryotic system; similarly, prokaryotic promoters are not recognized and do not function in eukaryotic cells.
- SD Shine-Dalgarno
- Promoters vary in their "strength" (i.e., their ability to promote transcription). For the purposes of expressing a cloned gene, it is desirable to use strong promoters to obtain a high level of transcription and, hence, expression of the gene. Depending upon the host system utilized, any one of a number of suitable promoters may be used. For instance, when cloning in E.
- promoters such as the T7 phage promoter, lac promoter, trp promoter, recA promoter, ribosomal RNA promoter, the P R and P L promoters of coliphage lambda and others, including but not limited, to lac ⁇ TV5, ompF, bla, Ipp, and the like, may be used to direct high levels of transcription of adjacent DNA segments. Additionally, a hybrid trp- lac ⁇ JV5 (tac) promoter or other E. coli promoters produced by recombinant DNA or other synthetic DNA techniques may be used to provide for transcription of the inserted gene.
- promoters such as the T7 phage promoter, lac promoter, trp promoter, recA promoter, ribosomal RNA promoter, the P R and P L promoters of coliphage lambda and others, including but not limited, to lac ⁇ TV5, ompF, bla, Ipp, and the like, may be used to direct high levels of transcription of adjacent
- Bacterial host strains and expression vectors may be chosen which inhibit the action of the promoter unless specifically induced.
- the addition of specific inducers is necessary for efficient transcription of the inserted DNA.
- the lac operon is induced by the addition of lactose or IPTG (isopropylthio- beta-D-galactoside).
- IPTG isopropylthio- beta-D-galactoside.
- Other operons, such as trp, pro, etc. are under different controls.
- Common promoters suitable for directing expression in mammalian cells include, without limitation, SV40, MMTV, metallothionein-1, adenovirus Ela, CMV, immediate early, immunoglobulin heavy chain promoter and enhancer, and RSV-LTR.
- the multiple nucleic acid molecules may all be placed under a single 5 ' regulatory region and a single 3 ' regulatory region, where the regulatory regions are of sufficient strength to transcribe and/or express the nucleic acid molecules as desired.
- Specific initiation signals are also required for efficient gene transcription and translation in prokaryotic cells. These transcription and translation initiation signals may vary in "strength” as measured by the quantity of gene specific messenger RNA and protein synthesized, respectively.
- the nucleic acid expression vector which contains a promoter, may also contain any combination of various "strong" transcription and/or translation initiation signals. For instance, efficient translation in E. coli requires a Shine-Dalgarno ("SD") sequence about 7-9 bases 5' to the initiation codon (ATG) to provide a ribosome binding site. Thus, any SD-ATG combination that can be utilized by host ribosomes may be employed.
- Such combinations include but are not limited to the SD-ATG combination from the cro gene or the N gene of coliphage lambda, or from the E. coli tryptophan E, D, C, B or A genes. Additionally, any SD-ATG combination produced by recombinant DNA or other techniques involving incorporation of synthetic nucleotides may be used. Depending on the vector system and host utilized, any number of suitable transcription and/or translation elements, including constitutive, inducible, and repressible promoters, as well as minimal 5' promoter elements, enhancers or leader sequences may be used.
- an antibiotic or other compound useful for selective growth of only the transgenic cells is added as a supplement to the media.
- the compound to be used will be dictated by the selectable marker element present in the plasmid with which the host was transformed. Suitable genes are those which confer resistance to gentamycin, G418, hygromycin, streptomycin, spectinomycin, tetracycline, chloramphenicol, and the like.
- reporter genes which encode enzymes providing for production of an identifiable compound, or other markers which indicate relevant information regarding the outcome of gene delivery, are also suitable. For example, various luminescent or phosphorescent reporter genes are also appropriate, such that the presence of the heterologous gene may be ascertained visually.
- An example of a marker suitable for the present invention is the green fluorescent protein (GFP) gene.
- the isolated nucleic acid molecule encoding a green fluorescent protein can be deoxyribonucleic acid (DNA) or ribonucleic acid (RNA, including messenger RNA or mRNA), genomic or recombinant, biologically isolated or synthetic.
- the DNA molecule can be a cDNA molecule, which is a DNA copy of a messenger RNA (mRNA) encoding the GFP.
- the GFP can be from Aequorea victoria (Prasher et al., "Primary Structure of the Aequorea Victoria Green- Fluorescent Protein," Gene l l l(2):229-233 (1992); U.S. Patent No. 5,491,084 to Chalfie et al., which are hereby incorporated by reference in their entirety).
- a plasmid encoding the GFP of Aequorea victoria is available from the ATCC as Accession No. 75547. Mutated forms of GFP that emit more strongly than the native protein are commercially available from Clontech Laboratories, Inc. (Palo Alto, California) and can be used for the same purpose. Indeed, any nucleic acid molecule encoding a fluorescent form of GFP can be used in accordance with the subject invention. Standard techniques are then used to place the nucleic acid molecule encoding GFP under the control of the chosen cell specific promoter.
- a nucleic acid molecule encoding a suitable cytokine, a promoter molecule of choice, including, without limitation, enhancers, and leader sequences; a suitable 3' regulatory region to allow transcription in the host, and any additional desired components, such as reporter or marker genes, are cloned into the vector of choice using standard cloning procedures in the art, such as described in Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Laboratory, Cold Spring Harbor, New York (1989); Ausubel et al, "Short Protocols in Molecular Biology," New York:Wiley (1999), and U.S. Patent No. 4,237,224 to Cohen and Boyer, which are hereby incorporated by reference in their entirety.
- the recombinant expression system is suited for the secretion of hydrophobic proteins in recombinant organisms such that the hydrophobic protein is properly folded and either directed to the periplasm of Gram-negative bacteria or secreted into the extracellular environment.
- One example of such an expression system is disclosed in U.S. Application Publ. No. 20110020868 to Coleman et al, which is hereby incorporated by reference in its entirety. The system described in Coleman utilizes a Pseudomonas fluorescens (P.
- fluorescens) secretion polypeptide selected from a mutant phosphate binding protein (pbp*), a protein disulfide isomerase A (dsbA), a protein disulfide isomerase C (dsbC), a CupA2, a CupB2, a CupC2, a NikA, a Flgl, a tetratricopeptide repeat family protein (ORF5550), a toluene tolerance protein (Ttg2C), or a methyl accepting chemotaxis protein (ORF8124) secretion signal, a Bacillus coagulans Bee secretion signal sequence, as well as biologically active variants, fragments, and derivatives thereof.
- pbp* mutant phosphate binding protein
- dsbA protein disulfide isomerase A
- dsbC protein disulfide isomerase C
- CupA2 a CupB2, a CupC2
- NikA a tetratricopeptide
- nucleic acid molecule encoding the peptide has been cloned into an expression vector, it is ready to be incorporated into a host.
- Recombinant molecules can be introduced into cells, without limitation, via transfection (if the host is a eukaryote), transduction, conjugation, mobilization, or electroporation, lipofection, protoplast fusion, mobilization, or particle bombardment, using standard cloning procedures known in the art, as described by Sambrook et al, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Springs Laboratory, Cold Springs Harbor, New York (1989), which is hereby incorporated by reference in its entirety.
- Suitable hosts include, but are not limited to, bacteria, yeast, and mammalian cells.
- Purified peptides may be obtained by several methods.
- the peptide is preferably produced in purified form (preferably at least about 80% or 85% pure, more preferably at least about 90%> or 95% pure) by conventional techniques.
- the peptide can be isolated and purified by centrifugation (to separate cellular components from supernatant containing the secreted peptide) followed by sequential ammonium sulfate precipitation of the supernatant.
- the fraction containing the peptide is subjected to gel filtration in an appropriately sized dextran or polyacrylamide column to separate the peptides from other proteins. If necessary, the peptide fraction may be further purified by HPLC.
- the peptide of interest may also contain a purification tag (such as poly-histidine (His 6 -), a glutathione-S-transferase (GST-), or maltose-binding protein (MBP-)), which assists in the purification but can later be removed, i.e., cleaved from the peptide following recovery.
- a purification tag such as poly-histidine (His 6 -), a glutathione-S-transferase (GST-), or maltose-binding protein (MBP-)
- GST- glutathione-S-transferase
- MBP- maltose-binding protein
- the peptides of the present invention are useful in formulating surfactant compositions for use in treating conditions involving disrupted lung.
- the surfactant compositions of the invention include one or more of the above -identified peptides in combination with one or more lipids.
- the one or more lipids include one or more synthetic ester-linked phospholipids or one or more phospholipase-resistant phospholipids or phosphonolipids.
- the one or more lipids include one or more naturally occurring
- phospholipids In yet another embodiment, a mixture of synthetic and naturally occurring phospholipids is utilized.
- Preferred synthetic lipid derivatives used in the surfactant compositions of the present invention are designed with molecular structures that are resistant to one or more endogenous phospholipases (A ls A 2 , and/or D) (Turcotte et al, "Chemical endogenous phospholipases
- Pulmonary Surfactant Dipalmitoyl Phosphatidylcholine Analog Biochim Biophys Acta 488:235-248 (1977), each of which is hereby incorporated by reference in its entirety).
- Compounds of this type can also have partial resistance to degradation by phospholipase C (Lin et al., "A Diether Phosphonolipid Surfactant Analog, DEPN-8, is Resistant to Phospholipase-C Cleavage,” Respiration 64:96-101 (1997), which is hereby incorporated by reference in its entirety).
- Phospholipase A 2 (PLA 2 ) is thought to play important roles in the pathogenesis of meconium aspiration syndrome (Kaapa, "Meconium Aspiration Syndrome: A Role for Phospholipase A 2 in the Pathogenesis?" Acta Paediatr. 90:365- 367 (2001); Schrama et al., "Phospholipase A 2 is Present in Meconium and Inhibits the Activity of Pulmonary Surfactant: An in vitro Study," Acta Paediatr.
- PLA 2 not only can degrade and deplete active surfactant glycerophospholipids, but also produces reaction byproducts such as lysophosphatidylcholine (LPC) and unsaturated free fatty acids that interact biophysically with intact surfactant to further impair surface activity (Holm et al., “Multiple Mechanisms of Lung Surfactant Inhibition,” Pediatr Res 46:85-93 (1999); Wang et al., “Additivity of Protein and Non-protein Inhibitors of Lung Surfactant Activity,” Am J Respir Crit Care Med 158:28-35 (1998); Hall et al,
- the phospholipase-resistant surfactants of this invention include one or more synthetic peptides combined with one or more phospholipase-resistant phospho-choline derivatives (analogs) and/or one or more phospholipase-resistant phospho-glycerol derivatives (analogs).
- phospholipase-resistant phospho-choline derivative or analog refers to a derivative of naturally occurring phospho-choline molecules in lung surfactant, where the derivatives are resistant to one or more of phosp ho lipases A ls A 2 , C, and D, and have a structural modification in one or more of the fatty acid chain-backbone linkage group (e.g., ether, thioether, etc.), phospho group, or the remainder of the head group including the choline group.
- the fatty acid chain-backbone linkage group e.g., ether, thioether, etc.
- the phospholipase-resistant phospho-choline derivative preferably has a structure according to formula (II)
- R 3 and R 4 are independently O, S, or S0 2
- R 3 and P are independently C8-C24 hydrocarbons.
- the hydrocarbon groups of R 3 and R 4 can be the same or different, and can be saturated, monounsaturated, or polyunsaturated hydrocarbons, although saturated and monounsaturated are preferred.
- Preferred hydrocarbons are C10-C22 hydrocarbons, more preferably C12-C20 hydrocarbons, most preferably C14-C18 hydrocarbons.
- the phospholipase-resistant phospho-choline derivative has a saturated R 3 group and a monounsaturated or polyunsaturated R 4 group.
- n is preferably an integer from 0 to 2.
- the Y 3 and Y 4 linker groups can be the same or different. According to one preferred embodiment, at least one of these linker groups is S or S0 2 , more preferably the Y 3 group. According to another embodiment, both Y 3 and Y 4 are S or S0 2 . According to a further embodiment, both Y 3 and Y 4 are O.
- Exemplary phospholipase-resistant phospho-choline derivatives include, without limitation, [(+)-trimethyl(3-phosphonopropyl)ammonium, mono(2,3- bis(hexadecyloxy)propyl ester] ("DEPN-8"); [( ⁇ )-trimethyl(3- phosphonopropyl)ammonium, mono(2-hexadec-9-enyloxy-3-hexadecyloxypropyl) ester] ("UnDEPN-8”); [(+)-trimethyl(3-phosphonopropyl)ammonium, mono(2-hexadecyloxy- 3-hexadecylsulfanylpropyl) ester] ("S-lipid”); [(+)-trimethyl(3- phosphonopropyl)ammonium, mono(2-hexadecyloxy-3 -hexadecylsulfonylpropyl) ester] ("S0 2
- phospholipase-resistant phospho-glycerol derivative or analog refers to a derivative of naturally occurring phospho-glycerol molecules in lung surfactant, where the derivative is resistant to one or more of phosp ho lipases A ls A 2 , C, and D, and has a structural modification in one or more of the fatty acid chain-backbone linkage group (e.g., ether, thioether, etc.), phospho group, or the remainder of the head group including the glycerol group.
- the fatty acid chain-backbone linkage group e.g., ether, thioether, etc.
- the phospholipase-resistant phospho-glycerol derivative is preferably a compound havin a structure according to formulae (la) or (lb)
- X is O or (CH 2 ) verse where n is an integer from 0 to 5, Y 1 and Y 2 are independently O, S, or S0 2 ; and Ri and R 2 are independently C8-C24 hydrocarbons.
- the hydrocarbon groups of Ri and R 2 can be the same or different, and can be saturated, monounsaturated, or polyunsaturated hydrocarbons, although saturated and monounsaturated are preferred.
- Preferred hydrocarbons are C10-C22 hydrocarbons, more preferably C12-C20 hydrocarbons, most preferably C14-C18 hydrocarbons.
- the phospholipase-resistant phospho-glycerol derivative has a saturated Ri group and a monounsaturated or polyunsaturated R 2 group.
- n is preferably an integer from 0 to 2.
- the molecular change at the level of the phosphate group in phosphono-lipid analogs is believed to confer structural resistance to Phospholipase D.
- the Yi and Y 2 linker groups can be the same or different. According to one preferred embodiment, at least one of these linker groups is S or S0 2 , more preferably the Yi group. According to another embodiment, both Yi and Y 2 are S or
- both Yi and Y 2 are O.
- the synthetic lipids of the present invention are designed to have several important molecular features.
- One such feature is the molecular modifications used in the Yi and Y 2 linkage groups between the fatty chains and the glycerol backbone, which confer structural resistance to phospholipase A 1 (PLAi) and A 2 (PLA 2 ).
- the phospholipase-resistant phospho- glycerol derivative has the structure according to formula (lb) and is present in the form of a salt, preferably a pharmaceutically acceptable salt.
- a salt preferably a pharmaceutically acceptable salt.
- pharmaceutically acceptable salt refers to those salts that retain the biological effectiveness and properties of the free bases.
- the salts are formed with any suitable cation including, without limitation, sodium, potassium, calcium, magnesium, zinc, and protonated amino acid residues.
- Other salts are known to those of skill in the art and can readily be adapted for use in accordance with the present invention.
- Exemplary phospholipase-resistant phospho-glycerol derivatives include, without limitation, 2,3-bis(hexadecyloxy)propyl 2, 3 -dihydroxypropyl hydrogen phosphate ("PG-A”); 2-((Z)-hexadec-9-enyloxy)-3-(hexadecyloxy)propyl 2,3- dihydroxypropyl hydrogen phosphate ("PG-B”); 2,3-bis(hexadecyloxy)propyl hydrogen 3,4-dihydroxybutylphosphonate (“PG-C”); 2-(hexadecyloxy)-3-(hexadecylthio)propyl
- ether linkages increase chain mobility and facilitate film respreading during cycling in the C16:0 diether analog compound DEPN-8 compared to DPPC (Turcotte et al., "Chemical Synthesis and Surface Properties of an Analog of the Pulmonary Surfactant Dipalmitoyl Phosphatidylcholine Analog," Biochim Biophys Acta 488:235-248 (1977); Liu et al., "Dynamic Interfacial Properties of Surface-Excess Films of Phospholipids and Phosphonolipid Analogs: I.
- DEPN-8 is also able to form interdigitated as well as normal opposed bilayers (Skita et al., "Bilayer Characteristics of a Diether Phosphonolipid Analog of the Major Lung Surfactant Glycerophospho lipid Dipalmitoyl
- PG phosphatidylglycerol
- the PG-related lipid analogs of the present invention are designed to facilitate interactions with the positive charges present in the headgroup of choline-related analogs and/or with positively charged amino acid residues present in synthetic peptides.
- the phospholipase-resistant phospholipids can be synthesized according to the procedures described in PCT Application Publ. No. WO 2008/011559 to Notter et al.; Schwan et al., "Synthesis and Activity of a Novel Diether Phosphonoglycerol in Phospholipase-resistant Synthetic Lipid:Peptide Lung Surfactants," Med Chem.
- the phospholipase-resistant lipid compounds can be present in the surfactant formulations as a racemic mixture, containing substantially equivalent amounts of stereoisomers.
- the phospholipase-resistant lipid compounds can be prepared or otherwise isolated, using known procedures, to obtain a single stereoisomer substantially free of its corresponding stereoisomer (i.e.,
- substantially pure it is intended that a stereoisomer is at least about 95% pure, more preferably at least about 98% pure, most preferably at least about 99% pure. Both racemic mixtures and substantially pure stereoisomers of the phospholipase-resistant lipid compounds can be used to prepare surfactant compositions of the present invention.
- the surfactants of this invention include one or more synthetic peptides combined with one or more naturally occurring phospholipids.
- exemplary naturally occurring phospholipids include, without limitation, DPPC (16:0 PC; l,2-dipalmitoyl-sn-glycero-3-phosphocholine); POPC
- a mixture of phosphocholine lipids and phosphoglycerol lipids are present, preferably at a mole ratio or weight ratio of total phosphoglycerol lipids to total phosphocholine lipids of between about 1 : 1 to about 1 : 100, preferably about 1 :3 to about 1 :50, more preferably about 1 :4 to about 1 :25.
- the ratio of POPG to total phosphocho lines is between about 1 : 1 up to about 1 : 100.
- the surfactant compositions of the present invention can further include any one or more of a non-phospho surfactant or a therapeutic agent including a pharmacological agent.
- non-phospho surfactant refers to surface active compounds that do not possess a phospho group (e.g., phosphate, phosphonate, etc.).
- exemplary non-phospho surfactants include, without limitation, a free fatty acid, hexadecanol, or cholesterol.
- Preferred free fatty acids include saturated and monounsaturated CIO to
- C24 hydrocarbons more preferably C12-C20 hydrocarbons, most preferably C14-C18 hydrocarbons. Of these, saturated hydrocarbons are preferred.
- the therapeutic agent can be any compound, nucleic acid, or peptide that is intended to be administered to the targeted lung tissues for therapeutic treatment of a disease or disorder involving the affected tissue.
- exemplary therapeutic agents include, without limitation, antioxidant enzymes, other antioxidant substances, anti-inflammatory agents (drugs, antibodies, receptor antagonists, and soluble receptors, etc.), vasoactive agents or agents synergistic with vasoactive agents, agents affecting leukocyte function or recruitment, agents affecting platelet aggregation, agents affecting resident pulmonary cells involved in host-defense, and agents participating in gene therapy.
- the surfactant composition includes, in addition to the surface active peptide, both a phospholipase-resistant phospho-glycerol derivative and a phospholipase-resistant phospho-choline derivative.
- the phospholipase-resistant phospho-glycerol derivative and the phospholipase-resistant phospho-choline derivative are present at a mole ratio or weight ratio of between about 1 : 1 to about 1 : 100, preferably about 1 :3 to about 1 :50, more preferably about 1 :4 to about 1 :25.
- the phospholipase-resistant phospho- choline derivative is present in an amount of about 65 to about 99 wt percent, more preferably between about 75 and about 98 wt percent; the phospholipase-resistant phospho-glycerol derivative is present in an amount up to about 25 wt percent, more preferably between about 1 and about 20 wt percent; and the surface active peptide is present in an amount of about 1 to about 15 wt percent, more preferably about 1 to about 7.5 wt percent, relative to total phospholipid (non-protein components).
- the total weight percentage of the lipid components equals 100 weight percent, and the peptide is added to this as a weight percentage based on the total phospholipid content.
- Composition A A:
- composition B (relative to total lipid MB DATK (SEQ ID NO: 4, reduced or oxidized), content) MB DATK Ala (SEQ ID NO: 5), or combinations thereof Composition B:
- Mini-SPCff_dog SEQ ID NO: 31
- Mini-SPCff_dog_leu SEQ ID NO: 31
- Composition C is a composition having Composition C:
- SMB DATK SEQ ID NO: 18, reduced or (relative to total lipid oxidized), MB DATK (SEQ ID NO: 4, reduced or oxidized), content
- MB DATK Ala SEQ ID NO: 5
- Mini-SPCff dog SEQ ID NO: 31
- Mini-SPCff dog SEQ ID NO: 31
- SMB DATK SEQ ID NO: 18, reduced or oxidized
- MB DATK Ala (SEQ ID NO: 5), or combinations thereof
- Composition E is a composition of Composition E:
- Mini-SPCff_dog SEQ ID NO: 31
- Mini-SPCff_dog_leu SEQ ID NO: 31
- Composition F is a composition of Composition F:
- SMB DATK SEQ ID NO: 18, reduced or
- MB DATK (SEQ ID NO: 4, reduced or oxidized), content) and MB DATK Ala (SEQ ID NO: 5)
- Mini-SPCff dog SEQ ID NO: 31
- Mini- relative to total lipid SPCff_dog_leu SEQ ID NO : 32
- Mini-SPCff_2_leu SEQ ID content
- Super Mini-SP-C SEQ ID NO: 35
- SP-Css ion- lock SEQ ID NO: 45
- SP-C ion-lock SEQ ID NO: 406
- SP-C ion-lock2ss SEQ ID NO: 197
- SP-C ion-lock-dog SEQ ID NO: 61
- SP-C ion-lock2ff SEQ ID NO: 69
- SP-C33ss_ion2 SEQ ID NO: 326)
- the surfactant compositions of the present invention can be used to treat lung tissue that is characterized by deficiency and/or dysfunction of endogenous surfactant (i.e., "surfactant deficient or dysfunctional lung tissue").
- endogenous surfactant i.e., "surfactant deficient or dysfunctional lung tissue”
- the deficiency of endogenous surfactant can be a reduced amount or an abnormal composition of endogenous surfactant (i.e., not enough is present or the composition thereof is ineffective) or the complete absence of an endogenous surfactant, and the surfactant dysfunction can be a reduced activity of endogenous surfactant either present intrinsically or acquired during disease.
- treatment of surfactant deficient and/or dysfunctional lung tissue is meant to include a prophylactic or therapeutic regimen that can inhibit onset of NRDS, for example, in premature infants, or the onset of acute lung injury (ALI) or the acute respiratory distress syndrome (ARDS) in patients of any age, or otherwise improve respiratory function, lung pressure-volume mechanics, or clinical outcome when administered for therapeutic treatment of a preexisting conditions such as acute or neonatal NRDS, or ALI, or ARDS.
- ALI acute lung injury
- ARDS acute respiratory distress syndrome
- treatment contemplates complete therapeutic resolution of a condition as well as improving conditions to minimize symptoms of NRDS or ALI/ARDS.
- the treatments in accordance with this aspect of the invention involve administering a surfactant composition of the present invention to a patient having lung tissue characterized by endogenous surfactant deficiency and/or dysfunction, where the administering is carried out under conditions effective to coat alveolar surfaces of the affected lung tissue with the surfactant composition, thereby treating the surfactant deficient and/or dysfunctional lung tissue.
- the patient to be treated can be a premature infant who is characterized by either the complete absence of endogenous surfactant or an ineffective amount of endogenous surfactant or an acquired dysfunction of endogenous surfactant during the clinical course.
- the surfactant composition of the present invention can be administered in a manner effective to prevent onset of neonatal respiratory distress syndrome (when administered immediately following intubation), or reduce the severity of respiratory deficit in neonatal respiratory distress syndrome and/or acute lung injury (when administered some time after initial intubation).
- Administration of the surfactant composition is preferably via aspiration, airway instillation, aerosolization, or
- Administration of the surfactant can be administered periodically over a course of treatment to maintain lung function in the infant, preferably until the infant's lung tissue is capable of producing sufficient endogenous surfactant to maintain lung function in the absence of intervention.
- the patient to be treated can also be an individual that otherwise should be able to produce active endogenous surfactant, but due to lung tissue disease or disorder either has deficient levels of endogenous surfactant or existing endogenous surfactant has become inhibited or inactivated in activity.
- the patient is a full-term infant, child, or adult.
- Endogenous surfactant production can be deficient or inactivated due to acute lung injury caused by pulmonary disease or infection, systemic disease or infection, or other direct or indirect causes such as burns, trauma, shock, aspiration syndromes, drug overdose, multiple blood transfusions, pancreatitis, or other known causes of ALI/ARDS.
- the surfactant composition of the present invention can be administered in a manner effective to reduce the severity of respiratory deficit in acute respiratory distress syndrome and/or acute lung injury.
- the surfactant composition may also be administered prophylactically to such patients to prevent the onset of ALI/ARDS.
- Administration of the surfactant composition is preferably via aspiration, airway instillation, aerosolization, or nebulization.
- Administration of the surfactant can be administered periodically over a course of treatment to maintain lung function in the individual being treated.
- Another aspect of the present invention relates to a method of delivering a therapeutic agent.
- a method of delivering a therapeutic agent By virtue of the surface activity of the compositions of the present invention, it is believed that the surfactant compositions of the present invention will readily form liposomal vesicles that can be used to deliver therapeutic agents to a patient.
- this method of the present invention includes introducing a therapeutic agent into a surfactant composition of the present invention under conditions effective to encapsulate the therapeutic agent in liposomal vesicles, and then administering the composition to a subject under conditions effective to deliver the therapeutic agent to a target tissue.
- the administration can be any suitable approach for delivery of the therapeutic agent to a target tissue, but preferably aspiration, airway instillation, aerosolization, nebulization, intranasal instillation, oral or nasogastic instillation, intraperitoneal injection, or intravascular injection.
- the target tissue can be lung tissue or a systemic tissue.
- the agent or agents to be delivered can be any pharmaceutical or therapeutic agent including those listed above as well as a systemic or local anti-tumor agent, a systemic or local gene therapy agent, a systemic or local anti-inflammatory agent or antioxidant, a systemic or local vasoactive agent, a systemic or local agent modifying immune responses, blood cells, or host-defense.
- SP-B Novel surfactant peptide
- the SP-B mimics MB datk (SEQ ID NO:4) and SMB datk (SEQ ID NO: 18) were engineered after first noting that the bend region in either Mini-B (MB) or Super Mini-B (SMB) (i.e., -PKGG-) promoted a compact helix-turn-helix motif, with the central bend region flanked by N- and C-terminal a-helices (Waring et al., "The Role of Charged Amphipathic Helices in the Structure and Function of Surfactant Protein B," J Peptide Res 66:364-374 (2005); Sarker et al, "Structure of Mini-B, a Functional Fragment of Surfactant Protein B, in Detergent Micelles," Biochemistry
- New surfactant peptide mimics based on native SP-C proteins were also developed with an iterative design process, in which native SP-C and potential SP-C mimic peptides were analyzed with computer algorithms and candidates were then synthesized for further testing.
- the focus in this example is on engineering SP-C mimics with short amino acid sequences that lack the covalently attached palmitoyl groups found in native SP-C proteins, both to simplify peptide synthesis and purification and also to minimize preparative costs.
- SEQ ID NO: 32 was identified by screening SP-C mimics based on the parent, native dog SP-C sequence (i.e., GIPCFPSSLKRLLIIVVVIVLVVVVIVGALLMGL, SEQ ID NO: 395). Prior studies have shown that native dog SP-C is a 34-residue SP-C protein, palmitoylated at Cys-4, which exhibits high a-helix and low ⁇ -sheet on Circular
- PASTA assigns relative energies to specific ⁇ -pairings of two sequence stretches of the same length (i.e., 10-100 pairings), and assumes that lower relative energies reflect enhanced ⁇ -sheet aggregation.
- PASTA calculated an exceptionally low energy of -28.5 for the segment 12-27 in a parallel pairing (Walther et al, "Critical Structural and Functional Roles for the N-terminal Insertion Sequence in Surfactant Protein B Analogs," PLoS One 5:e8672 (2010), which is hereby incorporated by reference in its entirety).
- SP-C peptides containing charged ion-pairs i.e., 'salt- bridges' or 'ion-locks', in which the cationic Arg + or Lys + residues interact with anionic GhT or Asp- residues
- follow-up synthesis and characterization of promising SP-C ion- lock mimics i.e., 'salt- bridges' or 'ion-locks', in which the cationic Arg + or Lys + residues interact with anionic GhT or Asp- residues
- thermodynamic penalty for replacing the hydrophobic residues of a transmembrane sequence with an 'ion-lock' pairing e.g., Lys + and GhT
- a 'ion-lock' pairing e.g., Lys + and GhT
- SP-Css ion-lock As one example of a SP-C ion-lock mimic, SP-Css ion-lock (SEQ ID NO:
- SP-Cff principally uses the human SP-C sequence or recombinant rSP-C (34 residues) as a template, but additionally substitutes Phe residues for the palmitoyl-Cys groups
- MPEx analysis of SP-Cff indicated a high hydropathy value (i.e., +11.31 for residues 12-30), consistent with this peptide inserting into surfactant lipids when a-helical (Snider et al., "MPEx: A Tool for Exploring Membrane Proteins," Protein Sci 18:2624-2628 (2009), which is hereby incorporated by reference in its entirety).
- SP-Cff ion-lock mimics lacking palmitoyls were next screened with PASTA and MPEx, using as a minimum criteria that successful SP-C mimics had a PASTA energy higher than -29.3 and a positive MPEx hydropathy.
- SP-Css ion-lock SEQ ID NO: 45
- PASTA energy was a promising surfactant-active mimic, with a PASTA energy of -22.2 for the parallel segment residues 7-27 and an MPEx hydropathy of +10.36 for residues 12-30.
- Hydropathy was calculated using the augmented Wimley- White whole-residue hydrophobicity scale with an explicit salt- bridge between Glu-20 and Lys-24 (Snider et al., "MPEx: A Tool for Exploring
- Example 8 Example 4 - Synthesis and Purification of Representative New SP-B and SP-C Peptide Materials
- Selected new SP-B and SP-C peptides were synthesized by solid-state methods, purified, and examined spectroscopically for use in subsequent examples documenting their activity when combined with synthetic glycerophospholipids or with phospholipase-resistant lipids in synthetic surfactant compositions (activity assessments are in subsequent examples).
- SP-C ion-lock-dog SP-C hybrid sequence N-terminus dog, and C- 61 terminus human with Glu20/Lys24 ion lock; 34
- SP-C ion-lock2ss SP-C human sequence bearing Ser substitutions at 197 positions 4 and 5, and Lysl5/Glul9, Glu20/Lys24 ion
- SP-C33ss_ion2 SP-C peptide bearing Ser substitutions at positions 4 326 and 5, Lysl5/Glul9, Glu20/Lys24 ion locks, and
- the crude peptide was then purified (better than 95%) by preparative HPLC using a VYDAC diphenyl or C8 (1" by 12" width by length) column at 20 ml/min.
- MB DATK was eluted from the column with a 0 to 100% (water to acetonitrile with 0.1% TFA as an ion pairing agent added to both aqueous and organic phases) linear gradient in one hour.
- the purified product was freeze-dried directly and the mass confirmed by Maldi TOF mass spectrometry.
- the disulfide linkages of the purified MB datk peptide were directed by using acid labile trityl (Trt)-protecting groups at cysteine positions 1 and 33, and at cysteine positions 4 and 27.
- the disulfide bonds between Cys-1 and Cys-33 and at 4 and 27 were formed by air oxidation for 24 h in trifluoroethanol: ammonium bicarbonate buffer (10 mM, pH 8.0).
- the disulfide connectivity was confirmed by mass spectrometry of the enzyme-digested fragments (trypsin, chymotrypsin).
- a reduced Mini-B DATK peptide (MB DATK Red) was similarly prepared, except that the oxidizing steps were omitted and the sulfide groups on cysteine residues 1 and 33 were blocked with N-ethylmaleimide (Waring et al., "The Role of Charged Amphipathic Helices in the Structure and Function of Surfactant Protein B,” J Peptide Res 66:364-374 (2005), which is hereby incorporated by reference in its entirety).
- SP-Css ion-lock (SEQ ID NO: 45) peptide was synthesized using a similar protocol developed for the parent SP-Cff peptide (Alonso et al., "Keeping Lung Surfactant Where It Belongs: Protein Regulation of Two-dimensional Viscosity,” Biophys J 89:266-273 (2005), which is hereby incorporated by reference in its entirety).
- the SP-Css ion-lock (SEQ ID NO: 45) carboxylated at the C-terminus was synthesized with the ABI 431 A Synthesizer using standard Fmoc protocols on a Leu- HMPB NOVAPEG resin.
- C-terminal carboxylated mimics from these SP-C peptide families are readily prepared with FastMocTM or standard Fmoc procedures on a Leu- HMPB NOVA resin using ABI 431 A, Symphony Multiple Peptide or Liberty
- This HLPC procedure better elutes hydrophobic peptides such as SP-Css ion- lock (SEQ ID NO: 45) with a run time of 1 h.
- the purified product was freeze-dried directly and the mass confirmed by Maldi TOF mass spectrometry as described above.
- Monomer Mini-C dog cf cys 5 that was carboxyl amidated at the C- terminus was synthesized using standard Fmoc protocol with double coupling for all residues and a Novachem Rink Amide MBHA resin (100-200 mesh) with the Symphony Multiple Peptide Synthesizer. Versions of SP-C peptides that are carboxyl amidated at the C-terminus may be synthesized similarly to those that are carboxylated at the C- terminus, replacing the Leu-HMPB NovaPEG resin with either the NovaPEG Rink
- the cleavage procedure for the Monomer Mini-C dog cf cys 5 involved standard Fmoc cleavage solution, i.e., neat TFA, with phenol-water, thioanisole, 1 ,2-ethanedithiol (10: 1 :0.5:0.25, v:v), and the mass of the crude monomer peptide was confirmed by Maldi TOFI in low mass reflectance mode using alpha matrix.
- the reduced crude monomer Mini-C dog cf cys 5 was oxidized in 20% DMSO for 48 hours at pH 7.0 (5 mM acetate buffer), then dried down in a speed-vac for 12 hours.
- SPCff_dog SEQ ID NO: 31
- Mini-SPCff_dog_leu SEQ ID NO: 32
- Mini-SPCff_2_leu SEQ ID NO: 34
- Mini-SPCff dog leu may exhibit high a-helix because it omits the C-terminal VVLIVVVIVGALLMGL sequence found in dog SP-C, which limits the number of H- bonded residues participating in ⁇ -sheet, and also because of the replacement of Val with Leu at residues 17, 18 and 19 (Almlen et al., "Concentration Dependence of a Poly- leucine Surfactant Protein C Analogue on in vitro and in vivo Surfactant Activity," Neonatology 92: 194-200 (2007); Almlen et al, "Alterations of the C-terminal End Do Not Affect in vitro or in vivo Activity of Surfactant Protein C Analogs," Biochim Biophys Acta S0005-2736(l 1)00028-9 (2011), each of which
- an SP-B mimic peptide (MB DATK Ox, MB
- DATK Red, MB DATK Ala, or MB DATK Ser was dissolved in 2,2,2- trifluoroethanol (TFE) and co-solvated with desired lipids dispersed in chloroform (TFE:Chloroform, 1 : 1, v:v).
- the desired lipids included one or more of: DEPN-8 (a phospholipase-resistant C16:0, C16:0 diether phosphono-phosphatidylcholine); PG-1 (a phospholipase-resistant C16:0, C16: l diether phosphono-phosphatidylglycerol); DPPC (dipalmitoyl phosphatidylcholine); POPC (palmitoyl-oleoyl-phosphatidylcholine); and POPG (palmitoyl-oleoyl-phosphatidylglycerol).
- DEPN-8 a phospholipase-resistant C16:0, C16:0 diether phosphono-phosphatidylcholine
- PG-1 a phospholipase-resistant C16:0, C16: l diether phosphono-phosphatidylglycerol
- DPPC dipalmitoyl phosphatidylcholine
- peptide-lipid film was then placed under high vacuum (1 mT) for 12 hours to remove residual solvent and sterile normal saline (0.9% by weight NaCl) adjusted to pH 7.0 with sodium bicarbonate (0.1 N). The hydrated film was then dispersed using a rotary evaporator at a temperature of 65°C for one hour prior to refrigerated storage at 5°C. Similar formulation procedures were used for synthetic surfactant compositions containing other SP-B mimic peptides and/or SP-C mimic peptides that were tested for activity in subsequent examples.
- Adsorption was measured following injection of a surfactant bolus beneath the interface of a stirred subphase at time zero.
- Surface pressure is the amount of surface tension lowering below that of the pure subphase (normal saline adjusted to pH 7.0) at 37 ⁇ 0.5 °C. Higher surface pressure equates to lower surface tension.
- CLSE calf lung surfactant extract
- DEPN-8 C16:0, C16:0 diether phosphono-PC (phosphatidylcholine); PG-1: C16:0, C16: l diether phosphono-PG.
- S-MB denotes
- Table 8 Minimum Surface Tensions of Resistant Synthetic Surfactants Containing DEPN-8, PG 1, and Super Mini-B (S-MB) During Pulsation on a Bubble Surfactometer
- Table 9 shows the rapid adsorption of representative phospholipase- resistant synthetic surfactants containing 9: 1 DEPN-8/PG-1 combined with 3% by
- glycerophospholipids and studied for in vitro and in vivo surfactant activities.
- glycerophospholipids (5:3:2 molar ratio DPPC:POPC:POPG).
- S- MB denotes "Super Mini-B”.
- the D ATK substitution in novel MB DATK Red and MB DATK Ox peptides in Table 10 also leads to improved adsorption activity relative to that previously reported for MB without the DATK substitution (for MB activity, see Walther et al, "Dynamic Surface activity of a Fully- Synthetic Phospholipase-Resistant Lipid/Peptide Lung Surfactant," PLoS ONE, 2(10): 1-10: el039. (2007), which is hereby incorporated by reference in its entirety).
- DPPC:POPC:POPG in sodium phosphate buffered saline (10 mM PBS, pH 7.4) indicated high secondary conformations for loop-turn (32.8%) and alpha-helix (27.4%). These secondary structures are comparable to those for either oxidized MB or SMB bound to DPPC or POPG (Walther et al., "Critical Structural and Functional Roles for the N-terminal Insertion Sequence in Surfactant Protein B Analogs," PLoS One 5:e8672 (2010), which is hereby incorporated by reference in its entirety).
- MB DATK Red likely adopts the active folding of oxidized MB in surfactant lipids, given that Molecular Dynamics (MD) simulations using GROMACS showed that MB DATK Red in a lipid- mimic, i.e., 35% TFE:water (35:65, v:v), rapidly assumes (i.e., -45 nanoseconds) the characteristic MB tertiary structure of helix-turn-helix.
- MD Molecular Dynamics
- Saline lavage produces surfactant deficiency, alveolar collapse and lung edema in ventilated rats and rabbits, and is a useful experimental model for human ARDS.
- a saline-lavage rabbit model for lung injury was thus used to compare synthetic surfactants, with lipids only as negative control. Restoration of lung function was assessed by serial monitoring of gas exchange and lung mechanics.
- Physiological activity results for selected synthetic SP-B peptides are shown below, and physiological activity results for selected synthetic SP-C peptides are included in following Example 8.
- experimental animals were commercially available young adult male New Zealand white rabbits whose respiratory function was followed during mechanical ventilation by measurements of serial arterial blood gases and pulmonary compliance over the first 2 hours after a standardized saline lavage protocol.
- the model reflected a relatively pure state of surfactant insufficiency in animals with mature lungs.
- Saline lavage administration was performed after induction of anesthesia, insertion of a venous line in a marginal ear vein, endotracheal intubation and initiation of mechanical ventilation, muscle paralysis, and insertion of a carotid arterial line.
- Heart rate, arterial blood pressure and rectal temperature were measured continuously.
- saline lavage was performed with repeated intratracheal instillation and removal of 30 mL of normal saline until the Pa02 dropped below 100 mm Hg (average 3 lavages).
- Maintenance fluid was provided by a continuous infusion of Lactated Ringer's solution at a rate of 10 ml/kg/h. Edema fluid appearing in the trachea was removed by suctioning.
- an experimental or control surfactant mixture was instilled into the trachea at a dose of 100 mg/kg body weight and a concentration of 35 mg/mL.
- the rabbits were ventilated using a Harvard volume-controlled animal ventilator (tidal volume 7.5 ml/kg, a positive end-expiratory pressure [PEEP] of 3 cm H 2 0, an inspiratory/expiratory ratio of 1 :2, 100% oxygen, and a respiratory rate to maintain a PaC02 at ⁇ 40 mm Hg).
- Airway flow and pressures and tidal volume were monitored continuously with a pneumotachograph connected to the endotracheal tube and a pneumotach system. Arterial pH and blood gases were done every 15 minutes.
- Oxidized SMB and MB were used as positive controls, because these SP-B mimics previously indicated high in vivo surfactant activities equal to those of native, full-length porcine SP-B in ventilated rats with ARDS (Walther et al, "Critical Structural and Functional Roles for the N-terminal Insertion Sequence in Surfactant Protein B Analogs," PLoS One 5:e8672 (2010), which is hereby incorporated by reference in its entirety).
- synthetic surfactant preparations were formulated by mixing synthetic lipids, consisting of 5:3:2 (weight ratio) DPPC :POPC :POPG, either alone (Lipids) or with 3.0% by weight
- Table 11 shows several representative Mini-SP-C peptides that all have very high adsorption when combined with synthetic ester linked phospholipids.
- Mini-SPCff dog The adsorption of surfactant compositions containing Mini-SPCff dog, Mini-SPCff dog leu, Mini-SP-C, or Mini-C dog cf_cys5 dimer in Table 11 is also significantly greater than that of the previously reported SP-C peptide SP-C33.
- Glycerophospholipids (5:3:2 molar ratio DPPC:POPC:POPG)
- Mini-SPCff_dog SEQ ID NO: 31 ;
- Mini-SPCff_dog_leu SEQ ID NO: 32;
- Mini-SPCff_2_leu SEQ ID NO: 34;
- Mini-C dog cf_cys5 dimer disulfide -linked dimer of Mini— C dog_cf monomers (SEQ ID NO: 33);
- DPPC Dipalmitoyl PC;
- POPC Palmitoyl-oleoyl-PC;
- POPG Palmitoyl-oleoyl-PG.
- novel Mini-SP-C peptides in Table 11 also have substantial added synthesis/stability advantages relative to full-length native SP-C or existing SP-C peptides such as SP-C33.
- novel Mini-SP-C peptides here have only about half the number of amino acid residues present in native SP-C or SP-C33, making them much easier and more cost-effective to synthesize.
- novel Mini-SP-C peptides are much more stable against the formation of amyloid-like forms or related non-specific structures that can increase viscosity and reduce shelf life in pharmaceutical applications.
- SP-C peptides synthesized and studied for surface activity included several ion-lock SP-C peptides. These peptides were synthesized with standard techniques (Waring et al, "The Role of Charged Amphipathic Helices in the Structure and Function of Surfactant Protein B,” J Peptide Res 66:364-374 (2005);
- SP-Cff represents the native sequence of SP-C
- SP-Cff represents the native sequence of SP-C
- SP-C33 represents the native sequence of SP-C
- SP-C mimic with elevated surfactant activity i.e., SP-C33
- SP-C mimic with a salt bridge at Glu-20 and Lys-24 i.e., SP-Css ion-lock; SEQ ID NO: 45.
- SP-C33 and SP-Css ion-lock were prepared as described earlier, and SP-Cff was also synthesized with standard techniques (Waring et al, "The Role of Charged Amphipathic Helices in the Structure and Function of Surfactant Protein B,” J Peptide Res 66:364-374 (2005); Walther et al, “Critical Structural and Functional Roles for the N-terminal Insertion Sequence in Surfactant Protein B Analogs," PLoS One 5:e8672 (2010), each of which is hereby incorporated by reference in its entirety).
- FTIR spectra were obtained for the above SP-C mimics in surfactant lipids (5:3:2 weight ratio
- FTIR spectra indicated predominant a-helix (i.e., -63%) for the SP-Css ion- lock in surfactant lipids, as opposed to the very high ⁇ -sheet (i.e., -59%) observed with the corresponding FTIR spectrum of its related parent SP-Cff without an ion-lock.
- SP-Css ion-lock The elevated a-helix and in vitro adsorption surface pressure noted for SP-Css ion-lock are similar to those of SP-C33, but here are achieved with a novel mechanism in which a single ion-lock (i.e., Glu-20, Lys-24) is incorporated into the transmembrane poly-Val core.
- Table 12 Adsorption of Synthetic Surfactant Compositions Containing a New SP-C Ion-lock Peptide Plus Synthetic Glycerophospholipids (5:3:2 molar ratio DPPC:POPC:POPG)
- SP- CSS was used as a positive control because it has significant in vitro adsorption (Table 11), and also has previously been reported to have high in vitro and in vivo surfactant activities (Almlen et al., "Synthetic surfactant based on analogues of SP-B and SP-C is superior to single-peptides in ventilated premature rabbits," Neonatology 998: 91 (2010); Almlen et al., "Alterations of the C-terminal end do not affect in vitro or in vivo activity of surfactant protein C analogs," Biochim Biophys Acta 1818:27-32 (2011) each of which is hereby incorporated by reference in its entirety).
- synthetic surfactant preparations were formulated by mixing synthetic lipids, consisting of 5:3:2 (weight ratio) DPPC:POPC:POPG, either alone (Lipids) or with 3.0% by weight SP-Css ion-lock (SEQ ID NO: 45), SP-Cff (SEQ ID NO: 45), SP-Cff (SEQ ID NO: 45), SP-Cff (SEQ ID NO: 45), SP-Cff (SEQ ID NO: 45), SP-Cff (SEQ ID NO: 45), SP-Cff (SEQ ID NO:
- SP-Css ion-lock was readily synthesized as purified peptide in large quantities using standard solid-phase peptide synthesis (SPPS) techniques. Moreover, the SP-Css ion- lock peptide requires only minimal alterations in the native sequence (i.e., insertion of the single ion-lock, Gly-20, Lys-24) to achieve both elevated a-helicity and high surfactant activity and stability, when compared to the poly-Leu substitution in SP- C33. This indicates that SP-C ion-locks may be cleared (i.e., catabolized) more readily by the normal salvage pathways in the lung. Hence, SP-C ion-lock peptides may be less toxic than the SP-C33 class of peptides, especially when administered in therapeutic applications for chronic conditions.
- SPPS solid-phase peptide synthesis
- This example shows the adsorption activity of representative synthetic surfactant compositions containing a new synthetic SP-B peptide and a new synthetic SP-C peptide combined with synthetic ester-linked glycerophospholipids or with phospholipase-resistant lipids.
- Surfactants were formulated in 0.15M NaCl with pH adjusted to 7.0 with 0.1N sodium bicarbonate as in Example 5, and adsorption methods were as in previous examples.
- Table 13 shows that synthetic surfactant compositions containing 5:3:2 (molar ratio) DPPC :POPC :POPG combined with MB DATK Red + Mini-SPCff dog
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne des compositions de tensioactifs pulmonaires synthétiques qui comportent un nouveau peptide actif de surface et un phospholipide, comprenant des dérivés de phosphoglycérol résistants à la phospholipase, des dérivés de phosphocholine résistants à la phospholipase, des phospholipides naturels, ou une combinaison de ceux-ci. L'invention porte également sur des utilisations desdites compositions de tensioactifs pour traiter les tissus pulmonaires à tensioactifs endogènes dysfonctionnant ou déficients et pour procurer des agents thérapeutiques.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13746107.5A EP2812018B1 (fr) | 2012-02-09 | 2013-02-11 | Nouveaux peptides sp-b et sp-c, tensioactifs pulmonaires synthétiques, et leurs utilisations |
EP18203081.7A EP3459556A1 (fr) | 2012-02-09 | 2013-02-11 | Synthétiques analogues du protein surfactant pulmonaire sp-c et leur utilisation |
US14/376,726 US9815869B2 (en) | 2012-02-09 | 2013-02-11 | SP-B and SP-C peptides, synthetic lung surfactants, and use thereof |
US15/788,883 US10358465B2 (en) | 2012-02-09 | 2017-10-20 | SP-B and SP-C peptides, synthetic lung surfactants, and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261596913P | 2012-02-09 | 2012-02-09 | |
US61/596,913 | 2012-02-09 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/376,726 A-371-Of-International US9815869B2 (en) | 2012-02-09 | 2013-02-11 | SP-B and SP-C peptides, synthetic lung surfactants, and use thereof |
US15/788,883 Division US10358465B2 (en) | 2012-02-09 | 2017-10-20 | SP-B and SP-C peptides, synthetic lung surfactants, and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013120058A2 true WO2013120058A2 (fr) | 2013-08-15 |
WO2013120058A3 WO2013120058A3 (fr) | 2015-06-25 |
Family
ID=48948169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/025532 WO2013120058A2 (fr) | 2012-02-09 | 2013-02-11 | Nouveaux peptides sp-b et sp-c, tensioactifs pulmonaires synthétiques, et leurs utilisations |
Country Status (3)
Country | Link |
---|---|
US (2) | US9815869B2 (fr) |
EP (2) | EP2812018B1 (fr) |
WO (1) | WO2013120058A2 (fr) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015024022A2 (fr) | 2013-08-16 | 2015-02-19 | University Of Rochester | Peptides conçus pour la modulation d'une barrière de jonction serrée |
WO2018096057A1 (fr) | 2016-11-24 | 2018-05-31 | Universiteit Gent | Particules comprenant une protéine b tensioactive et un ou plusieurs lipides |
WO2018115013A1 (fr) | 2016-12-22 | 2018-06-28 | Chiesi Farmaceutici S.P.A. | Combinaison thérapeutique comprenant un surfactant pulmonaire et un stéroïde pour le traitement de la dbp évolutive |
US10391151B2 (en) * | 2015-06-29 | 2019-08-27 | The Trustees Of The Stevens Institute Of Technology | Dilute surfactant or isolated surfactant protein solution for the reduction of surface tension in the lung |
WO2019206731A1 (fr) | 2018-04-23 | 2019-10-31 | Chiesi Farmaceutici S.P.A. | Combinaison thérapeutique comprenant un tensioactif pulmonaire et un stéroïde pour la prophylaxie de la dbp |
EP3452041A4 (fr) * | 2016-03-07 | 2020-11-11 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Compositions et procédés pour l'administration d'agonistes de pparv, peptides tensioactifs et phopholipides |
WO2020247347A1 (fr) | 2019-06-05 | 2020-12-10 | University Of Rochester | Nouveaux inhibiteurs conçus pour la formation de jonctions serrées |
WO2021151853A1 (fr) | 2020-01-28 | 2021-08-05 | Chiesi Farmaceutici S.P.A. | Polypeptides ayant des propriétés améliorées |
WO2022155615A1 (fr) * | 2021-01-15 | 2022-07-21 | The Trustees Of The Stevens Institute Of Technology | Procédés de double administration pour le traitement de la détresse respiratoire |
US20230107377A1 (en) * | 2015-12-17 | 2023-04-06 | Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center | Synthetic lung surfactant with enhanced stability and effectiveness |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
US5491084A (en) | 1993-09-10 | 1996-02-13 | The Trustees Of Columbia University In The City Of New York | Uses of green-fluorescent protein |
WO2008011559A2 (fr) | 2006-07-20 | 2008-01-24 | University Of Rochester | Tensioactif pulmonaire synthetique et utilisation associée |
US7538090B1 (en) | 2004-05-21 | 2009-05-26 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Exogenous surfactant protein B mimic |
US20110020868A1 (en) | 2007-01-31 | 2011-01-27 | Pfenex, Inc. | Bacterial leader sequences for increased expression |
WO2011115538A1 (fr) | 2010-03-18 | 2011-09-22 | Spiber Technologies Ab | Production de protéines et de polypeptides |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3073789A (en) * | 1988-03-31 | 1989-10-05 | Abbott Laboratories | Drug delivery using pulmonary surfactant to facilitate absorption |
DE4418936A1 (de) * | 1994-05-31 | 1996-02-08 | Byk Gulden Lomberg Chem Fab | Polypeptid |
EP1481665A1 (fr) * | 2003-05-30 | 2004-12-01 | CHIESI FARMACEUTICI S.p.A. | Nouveaux mélanges lipidiques pour tensioactifs synthétiques |
JP5405307B2 (ja) * | 2006-10-13 | 2014-02-05 | キエージ・フアルマチエウテイチ・エツセ・ピ・ア | 改善された性質を有する再構成サーファクタント |
EP2022798A1 (fr) * | 2007-08-09 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | Peptides synthétiques de surfactant pulmonaire |
US8399406B2 (en) | 2009-06-05 | 2013-03-19 | Chiesi Farmaceutici S.P.A. | Reconstituted surfactant composition containing analogs of surfactant protein B (SP-B) and surfactant protein C (SP-C) |
-
2013
- 2013-02-11 US US14/376,726 patent/US9815869B2/en active Active
- 2013-02-11 EP EP13746107.5A patent/EP2812018B1/fr active Active
- 2013-02-11 EP EP18203081.7A patent/EP3459556A1/fr active Pending
- 2013-02-11 WO PCT/US2013/025532 patent/WO2013120058A2/fr active Application Filing
-
2017
- 2017-10-20 US US15/788,883 patent/US10358465B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
US5491084A (en) | 1993-09-10 | 1996-02-13 | The Trustees Of Columbia University In The City Of New York | Uses of green-fluorescent protein |
US7538090B1 (en) | 2004-05-21 | 2009-05-26 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Exogenous surfactant protein B mimic |
WO2008011559A2 (fr) | 2006-07-20 | 2008-01-24 | University Of Rochester | Tensioactif pulmonaire synthetique et utilisation associée |
US20110020868A1 (en) | 2007-01-31 | 2011-01-27 | Pfenex, Inc. | Bacterial leader sequences for increased expression |
WO2011115538A1 (fr) | 2010-03-18 | 2011-09-22 | Spiber Technologies Ab | Production de protéines et de polypeptides |
Non-Patent Citations (114)
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015024022A2 (fr) | 2013-08-16 | 2015-02-19 | University Of Rochester | Peptides conçus pour la modulation d'une barrière de jonction serrée |
US10391151B2 (en) * | 2015-06-29 | 2019-08-27 | The Trustees Of The Stevens Institute Of Technology | Dilute surfactant or isolated surfactant protein solution for the reduction of surface tension in the lung |
US20240158471A1 (en) * | 2015-12-17 | 2024-05-16 | Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center | Synthetic lung surfactant with enhanced stability and effectiveness |
US20230107377A1 (en) * | 2015-12-17 | 2023-04-06 | Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center | Synthetic lung surfactant with enhanced stability and effectiveness |
US11179446B2 (en) | 2016-03-07 | 2021-11-23 | Lundquist Institute For Biomedical Innovation At Harbor—Ucla Medical Center | Compositions and method for administering PPARgamma agonists, surfactant peptides and phosopholipids |
US11951158B2 (en) | 2016-03-07 | 2024-04-09 | Lindquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center | Compositions and methods for administering PPARγ agonists, surfactant peptides and phospholipids |
EP3452041A4 (fr) * | 2016-03-07 | 2020-11-11 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Compositions et procédés pour l'administration d'agonistes de pparv, peptides tensioactifs et phopholipides |
US11213573B2 (en) | 2016-11-24 | 2022-01-04 | Universiteit Gent | Particles comprising surfactant protein B and one or more lipids |
WO2018096057A1 (fr) | 2016-11-24 | 2018-05-31 | Universiteit Gent | Particules comprenant une protéine b tensioactive et un ou plusieurs lipides |
WO2018115013A1 (fr) | 2016-12-22 | 2018-06-28 | Chiesi Farmaceutici S.P.A. | Combinaison thérapeutique comprenant un surfactant pulmonaire et un stéroïde pour le traitement de la dbp évolutive |
WO2019206731A1 (fr) | 2018-04-23 | 2019-10-31 | Chiesi Farmaceutici S.P.A. | Combinaison thérapeutique comprenant un tensioactif pulmonaire et un stéroïde pour la prophylaxie de la dbp |
WO2020247347A1 (fr) | 2019-06-05 | 2020-12-10 | University Of Rochester | Nouveaux inhibiteurs conçus pour la formation de jonctions serrées |
WO2021151853A1 (fr) | 2020-01-28 | 2021-08-05 | Chiesi Farmaceutici S.P.A. | Polypeptides ayant des propriétés améliorées |
WO2022155615A1 (fr) * | 2021-01-15 | 2022-07-21 | The Trustees Of The Stevens Institute Of Technology | Procédés de double administration pour le traitement de la détresse respiratoire |
Also Published As
Publication number | Publication date |
---|---|
WO2013120058A3 (fr) | 2015-06-25 |
EP2812018A4 (fr) | 2016-10-19 |
EP2812018A2 (fr) | 2014-12-17 |
US20150125515A1 (en) | 2015-05-07 |
US9815869B2 (en) | 2017-11-14 |
US10358465B2 (en) | 2019-07-23 |
EP3459556A1 (fr) | 2019-03-27 |
US20180037610A1 (en) | 2018-02-08 |
EP2812018B1 (fr) | 2018-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10358465B2 (en) | SP-B and SP-C peptides, synthetic lung surfactants, and use thereof | |
US9447127B2 (en) | Synthetic lung surfactant and use thereof | |
DK2673296T3 (en) | LIPOPROTEIN COMPLEXES AND PREPARATION AND APPLICATIONS THEREOF | |
EP1335938B1 (fr) | Constructions d'apolipoproteines | |
US11827690B2 (en) | ApoC-II mimetic peptides | |
JP5441904B2 (ja) | 合成肺サーファクタントペプチド | |
EP3393489A1 (fr) | Surfactant pulmonaire synthétique à stabilité et efficacité augmentées | |
EA042134B1 (ru) | МИМЕТИЧЕСКИЕ ПЕПТИДЫ apoC-II | |
AU2008201887A1 (en) | Apolipoprotein analogues | |
ES2356181T3 (es) | Construcción de apolipoproteínas. | |
PT1335938E (pt) | Construções de apolipoproteínas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13746107 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14376726 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013746107 Country of ref document: EP |